Latest Mauna Kea (MKEAF) Headlines Mauna Kea

New Post Public Reply Private Reply Replies (0) Message Board

Mar 10, 2014 at 2:13 PM

Latest Mauna Kea (MKEAF) Headlines

Mauna Kea Technologies Receives 510(k) Regulatory Clearance from U.S. FDA for Cellvizio in Urology
Business Wire - Wed Mar 05, 11:26AM CST
--Company makes further progress in positioning optical biopsy technology for new global market opportunities

Mauna Kea Technologies Installs First Cellvizio System in India at Apollo Gleneagles Hospital Kolkata
Business Wire - Wed Feb 19, 11:16AM CST
Regulatory News :

Mauna Kea Technologies Announces Centers for Medicare and Medicaid Services Set New Physician Payments for Upper GI Endoscopy with Cellvizio(R) Optical Endomicroscopy
Business Wire - Mon Jan 13, 10:44AM CST
Regulatory News :

Mauna Kea Technologies Announces Its 2013 FY Sales
Business Wire - Wed Jan 08, 11:54AM CST
--Confirmation of good Asia-Pacific development

Mauna Kea Technologies Partners with the Imperial College of London to Advance Research and Applications of Optical Biopsy with Cellvizio
Business Wire - Thu Dec 12, 11:28AM CST
Regulatory News:

Mauna Kea Technologies : CE Mark for a Complete Range of Probes Dedicated to Urology
Business Wire - Thu Nov 21, 10:45AM CST
Regulatory News :

Mauna Kea Technologies Launches EVA, a Unique Optical Biopsy Operating System Creating a Completely Seamless Customer Experience
Business Wire - Thu Nov 14, 11:14AM CST
Regulatory News :

Mauna Kea Technologies : First Use of Optical Biopsy with Cellvizio(R) in Robotic Assisted Prostatectomy Presented at 31st World Congress of Endourology
Business Wire - Tue Nov 05, 10:45AM CST
Regulatory News:

Mauna Kea Technologies Reports Third Quarter 2013 Sales Up 32 % to EUR2.73m
Business Wire - Thu Oct 10, 11:00AM CDT
--Record Q3 probe sales of 720 KEUR

Mauna Kea Technologies Announces Strong Presence at Asia-Pacific Digestive Week / World Congress of Gastroenterology 2013
Business Wire - Thu Sep 19, 12:30AM CDT
--Live procedures will be performed from Changhai Hospital, The Second Military Medical University, in Shanghai, by world expert Dr. Marc Giovannini

Mauna Kea Technologies Reports Financial Results for Half-Year 2013
Business Wire - Fri Aug 30, 10:45AM CDT
--Stable operating expenses

Mauna Kea Technologies Announces Global Expansion of Cellvizio LAB Distribution Network in Pre-Clinical Research
Marketwire - Thu Jul 25, 10:58AM CDT
Mauna Kea Technologies (NYSE Euronext: MKEA), leader in the optical biopsy market and developer of Cellvizio(R), the fastest way to see cancer, has entered several distribution agreements for its line of Cellvizio LAB products, including the Cellvizio Dual Band, for pre-clinical research.

Mauna Kea Technologies Reports Strong Second Quarter 2013 Sales Growth of +33% to EUR 2.5M
Marketwire - Tue Jul 16, 10:45AM CDT
Mauna Kea Technologies (EURONEXT PARIS: MKEA), leader in the optical biopsy market and developer of Cellvizio(R), the fastest way to see cancer, today announced sales results for the fiscal second quarter, ended June 30, 2013.

Mauna Kea Technologies Enters Into Major Cellvizio(R) Distribution Agreement With a Leading Japanese Medical Device Company
Marketwire - Thu Jun 13, 10:45AM CDT
Mauna Kea Technologies (EURONEXT PARIS: MKEA), leader in the optical biopsy market and developer of Cellvizio(R), the fastest way to see cancer, reported that it has entered an exclusive distribution agreement in Japan with AMCO Inc. for a five-year period. This partnership further strengthens Mauna Kea Technologies' ties with the Japanese market, and is a major step forward in the company's efforts to obtain regulatory approval in the world's second largest endoscopy device market after the US.

New Data on Cellvizio Presented at DDW 2013 Suggests That Optical Biopsies May Help Confirm and Rule Out Pancreatic Cystic Tumors*
Marketwire - Wed May 22, 10:45AM CDT
Mauna Kea Technologies (NYSE Euronext: MKEA), leader in the optical biopsy market and developer of Cellvizio(R), the fastest way to see cancer, today announced that optical biopsies using a microscope so tiny it fits through a small needle show clear cellular-level images inside pancreatic cysts, which could assist physicians in the diagnosis of pancreatic cystic tumors and help patients with benign cysts avoid unnecessary surgery, according to new data presented at Digestive Disease Week 2013, which concludes here today.

Mauna Kea Technologies Announces Strongest Scientific Exposure Ever With More Than 40 Communications on Cellvizio(R) at Digestive Disease Week 2013
Marketwire - Fri May 17, 12:30AM CDT
Mauna Kea Technologies (EURONEXT PARIS: MKEA), leader in the optical biopsy market and developer of Cellvizio(R), the fastest way to see cancer, today announced that 41 presentations at Digestive Disease Week (DDW) 2013 will highlight the use of optical biopsy across many of the most pervasive diseases in the gastrointestinal tract. Sixteen of the communications will be delivered through oral presentations and seven presentations will focus on needle-based optical biopsies, the newest application of Cellvizio technology that allows physicians to see cellular structures inside pancreatic cysts in the digestive tract in real time. DDW 2013 runs from May 18 to 21 in Orlando.

Mauna Kea Technologies gets FDA approval to market AQ-Flex 19 miniprobe for fine needle aspiration procedures
M2 - Tue Apr 30, 12:01PM CDT
Mauna Kea Technologies (Euronext Paris:MKEA), a medical device company focused on the optical biopsy market, confirmed today that the US Food and Drug Administration (FDA) has cleared the AQ-Flex 19 miniprobe to provide real-time optical biopsies during endoscopic ultrasound-guided fine needle aspiration (EUSFNA) procedures in the digestive tract.

FDA Grants Mauna Kea Technologies 510(k) Clearance to Market AQ-Flex(TM) 19 Miniprobe for Fine Needle Aspiration Procedures
Marketwire - Tue Apr 30, 9:39AM CDT
Mauna Kea Technologies (NYSE Euronext: MKEA), leader in the optical biopsy market and developer of Cellvizio(R), the fastest way to see cancer, today announced that the U.S. Food and Drug Administration (FDA) has cleared the AQ-Flex(TM) 19 miniprobe to provide real-time optical biopsies during endoscopic ultrasound-guided fine needle aspiration (EUSFNA) procedures in the digestive tract. This represents the sixth U.S. regulatory clearance for Mauna Kea Technologies' Cellvizio or one of its dedicated miniprobes, which already obtained the CE mark in Europe.

Mauna Kea Technologies Announces Highlights of 5th Annual International Conference of Cellvizio(R) Users (ICCU)
Marketwire - Tue Apr 23, 10:45AM CDT
Mauna Kea Technologies (NYSE Euronext: MKEA), leader in the optical biopsy market and developer of Cellvizio(R), the fastest way to see cancer, today announced highlights from the 5th Annual International Conference of Cellvizio Users (ICCU) held in Versailles, France, from April 5 to 7. Over 200 international optical biopsy experts -- a 70% increase in attendance over the 2012 meeting -- representing 17 countries and a variety of specialties including digestive endoscopy, pulmonology, urology, surgery, otorhinolaryngology, pathology and pre-clinical research gathered to review and discuss the latest research and impact of optical biopsy on clinical care.

Mauna Kea Technologies Reports First Quarter 2013 Sales Up 11% to EUR 1.8m
Marketwire - Tue Apr 16, 10:45AM CDT
Mauna Kea Technologies (EURONEXT PARIS: MKEA), leader in the optical biopsy market and developer of Cellvizio(R), the fastest way to see cancer, today announced its sales for the first quarter of the year ended March 31, 2013.

Mauna Kea Technologies (MKEAF) Stock Research Links

MKEAF Board Company Profile Buy Rating Time & Sales News Filings Financials

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Globe Life Faces 8% Stock Dip Amidst Legal Scrutiny

Trouble Brews for Globe Life Investors Brace yourselves, folks. Globe Life Inc. (NYSE: GL) has found itself slap-bang in the middle of a potentially messy legal quagmire. The $7 million in excess Medicare Supplement claims that popped up due to a snail-like processing delay by the Centers for Medicare & Medicaid Services (CMS) have sent investors scrambling. And oh boy,...

Dysolve Sheds Light on Dyslexia with AI Breakthrough

Turning the Page for Dyslexic Learners The narrative around dyslexia is getting a fresh edit, and it's not just another educational theory on some dusty shelf. Nope, Dysolve, with its trailblazing AI technology, is flipping the script for countless individuals grappling with dyslexia. This innovative breakthrough is reaching for the stars, aiming to demolish the barriers...

Compal and ARC Cloud Forge AI Partnership

AI Infrastructure: A New Era of Collaboration Well, here's one that's got my old trader veins throbbing with excitement. Compal Electronics and ARC Cloud are shaking hands in a deal that could sketch out a bold new chapter in AI infrastructure. This ain't your run-of-the-mill tech announcement; it's a strategic dance aimed at supercharging the very backbone of large-scale...

Ademi LLP Questions RRC Buyout Deal's Fairness

Unease Surrounds RRC's Potential Acquisition by EQT Let’s talk about a messy situation brewing with Range Resources Corporation (NYSE: RRC). The lawyers at Ademi LLP are poking around in the shadows of a proposed buyout by EQT Corporation, questioning whether the deal is legit—or if someone’s getting the short end of the stick. It’s all happening in a climate...

Exploring Family, Faith, and Forgiveness in New Book

Diving into the Depths of Faith and Forgiveness T.L. Dennis ain't just spinning a yarn about his childhood in "A Conversation with a Dead Father". This is a deep dive into the gritty realities of his relationship with his old man, seasoned with the salt of personal struggles and spiritual redemption. The pages of this book open at the one place none of us look for good...

Ex-Army Officer Questions Faith in New Book

A New Take on Age-Old Questions Diving into religion and philosophy from a combat veteran's perspective isn't your usual day job, but heck, Joe A. Putnam decided to tackle it head-on. In his latest book, "Hey God…Are You Still There?" Putnam doesn't just ponder whether the man upstairs is listening—he's challenging us all to think about it. Exploring Faith Through...

Keeper Security Shines in Gartner's 2026 PAM Report

Recognition That Stands Out When you're in the security game, being flagged in the Gartner® Magic Quadrant™ is like getting the thumbs-up from the industry's toughest critic. Keeper Security just snagged that recognition for the second year straight, and what's putting feathers in their cap? A completeness of vision and the chops to execute—no small feat in the wild...

Key Sewer Line Damage Signs Homeowners Often Ignore

Spotting Trouble Beneath the Surface Now, when was the last time you eyeballed your home’s plumbing with more than a passing glance? Most folks don’t give their sewer lines two thoughts until something foul pops up. Plumbing expert Jessica Gerdeman from Heggemann, Inc. in Warrenton, Missouri, isn’t just blowing hot air when she points out the indicators of looming...

TELUS Digital Named a Key Player in T&S Services 2026

Climbing the Ranks It’s not often you see a tech outfit surge ahead and pull off the kind of leaps TELUS Digital just managed. According to the Everest Group’s 2026 Trust and Safety Services PEAK Matrix® Assessment, TELUS Digital emerged as a Leader for the first time, riding high on advanced AI initiatives. Not just a pat on the back—that’s a big deal...

HDR: Revolutionizing Future Video Entertainment Experiences

HDR: The Unsung Hero of Video Quality Folks, let’s not kid around—high dynamic range (HDR) is no longer just the flashy chrome on the entertainment industry's Cadillac. It’s becoming the engine. Parks Associates’ recent snoop into the trends—that’s right, fresh off the presses from Plano, Texas—makes it clear: HDR is set to remake how we consume video on...